molecule generator News
-
Quantum-Si to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing the first-next generation single-molecule protein sequencing platform, today announced that it will be participating in the Morgan Stanley 20th Annual Global Healthcare Conference taking place at the Sheraton New York, NY, on September 12-14, ...
-
Quantum-Si to Participate in the 16th Annual Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing the first-next generation single-molecule protein sequencing platform, today announced that it will be participating in the 16th Annual Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum taking place at the Westin New ...
-
Quantum-Si’s Next-Generation Single-Molecule Protein Sequencing Technology Published in Science, Signaling New Era of Life Science and Biomedical Research
Key Takeaways: Next-generation single-molecule protein sequencing technology is poised to transform the science and research community’s understanding of the proteome by unlocking unprecedented insights about the human body - just as the advent of next-generation DNA sequencing has revolutionized our knowledge of the human genome over the past two decades. Through its real-time amino ...
-
Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment
Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced its nomination of a novel preclinical candidate (PCC) targeting 3C-like (3CL) protease for the treatment of COVID-19. Insilico's PCC is an orally available 3CL protease inhibitor with a novel structure generated using Insilico's AI platform. The compound can be efficiently ...
-
Sibylla Biotech will use its Drug Discovery platform to modulate the activity of targets supplied by Takeda
Sibylla PPI-FIT technology identifies novel druggable pockets in the intermediate folding states of proteins Sibylla intends to market the PPI-FIT technology platform-as-a-service‚ to the biotechnology and pharmaceutical industries. It also plans to generate its own in-house proprietary pipeline Verona (Italy), May 18th 2021 – Sibylla Biotech announced a research collaboration with ...
-
Beijing Tide Pharmaceutical and Insilico Medicine enter into an agreement for cancer therapy
Beijing Tide Pharmaceutical Co., Ltd. (Tide), a subsidiary of Sino Biopharmaceutical Limited, and Insilico Medicine, an artificial intelligence company developing end-to-end drug discovery pipelines, announced today that they are entering a collaboration, applying artificial intelligence (AI) technology to drug discovery, to jointly accelerate the process for multiple types of cancer treatment. ...
-
Orbit Discovery awarded Innovate UK grant to expand high throughput cell-based functional screening platform capabilities in peptide drug discovery
Oxford, United Kingdom, 13th June, 2022: Orbit Discovery Ltd., (“Orbit”) a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, has been awarded a Smart grant by Innovate UK, the UK’s innovation agency. Totalling £472,000, the grant will facilitate the ...
-
Creative Proteomics Lipidomics Upgrades Its Medium-Chain and Long-Chain Fatty Acids Analysis Service
Lipidomics, a platform developed by Creative Proteomics, is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomic research services for biomedical institutions as well as biotechnological and pharmaceutical companies. The company has recently upgraded its medium-chain and long-chain fatty acid analysis service. This service can provide reflections on lipid metabolism, glucose ...
-
Tal Zaks Joins Strategic Advisory Board at Deep Genomics
Deep Genomics, the leading AI therapeutics company, welcomes Tal Zaks, M.D., Ph.D., to its Strategic Advisory Board, effective today. Deep Genomics uses AI and machine learning to program and prioritize transformational nucleotide-based therapeutics for genetic diseases. As Chief Medical Officer at Moderna, Zaks successfully led a team that pioneered the field of mRNA therapeutics and drove ...
-
Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers
Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated a preclinical candidate (PCC) targeting methionine adenosyltransferase 2A (MAT2A) from AI-designed molecules for the treatment of methylthioadenosine phosphorylase (MTAP)-deleted cancers. The PCC is part of Insilico's growing ...
-
Insilico Medicine Initiates First-in-Human Study of ISM001-055, a Novel Drug Discovered Using Insilico`s Proprietary End-to-end Artificial Intelligence Platform
Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the first healthy volunteer has been dosed in a first-in-human microdose trial of ISM001-055. ISM001-055 is a potentially first-in-class small molecule inhibitor of a novel biological target discovered by Pharma.AI, Insilico Medicine's end-to-end AI-powered drug discovery platform. ...
-
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA (pembrolizumab)
ATG-037 is Antengene’s oral small molecule CD73 inhibitor; KEYTRUDA® (pembrolizumab) is MSD’s anti-PD-1 therapy The clinical trial collaboration will focus on evaluating ATG-037 as a monotherapy and in combination with KEYTRUDA® for the treatment of locally advanced or metastatic solid tumors The study of ATG-037 monotherapy started enrolling patients in Q2 2022 and will ...
-
Creative Enzymes Launches Enzyme Conjugation Service for Various Research Needs
Creative Enzymes, the world’s leading diagnostic enzyme production company, is committed to providing customers with various enzyme products and services for medical and research diagnosis. Relying on its professional team and the most advanced technology, as well as high-quality products and services, it has gained a solid reputation. Recently, the company has recently launched enzyme ...
-
CD ComputaBio Launches the In Silico PPI Prediction Service to Aid in Drug Action Mechanism Research
CD ComputaBio, a reliable computational biology service provider located in New York, is always hammering at research and trials in order to provide customers with access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. Recently, the product manager announced the launch of the in silico protein-protein interactions prediction service to predict ...
-
NIH Scientists Determine How Environment Contributes to Several Human Diseases
Using a new imaging technique, National Institutes of Health researchers have found that the biological machinery that builds DNA can insert molecules into the DNA strand that are damaged as a result of environmental exposures. These damaged molecules trigger cell death that produces some human diseases, according to the researchers. The work, appearing online Nov. 17 in the journal Nature, ...
-
Antengene Announces IND Approval for the Phase I STAMINA-001 Study to Evaluate ATG-037 (CD73 Inhibitor) for the Treatment of Locally Advanced or Metastatic Solid Tumors in China
ATG-037, an inhouse asset developed by Antengene and with global rights, has been approved to enter clinical studies in Australia and China, thus becoming the first oral small molecule CD73 inhibitor entering the clinical-stage in China and the wider Asia Pacific region. ATG-037 IND in Australia has been started enrolling in that phase I study. -The STAMINA-001 study will evaluate ATG-037 as a ...
-
OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases
Dr. Elias Zerhouni, ModeX Chairman, former President of Global R&D at Sanofi and former NIH Director, named President and Vice Chairman of OPKO Dr. Gary Nabel, ModeX President and CEO, former Chief Scientific Officer at Sanofi and founder of NIH’s Vaccine Research Center, joins OPKO as Chief Innovation Officer and a member of OPKO’s Board of Directors Alexis Borisy, ModeX Lead ...
-
Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022
Galapagos NV (Euronext & NASDAQ: GLPG) today held its R&D Day 2022, featuring presentations of key opinion leaders and company management on the strategic, scientific, and commercial progress at the company. The company also presented its financial results for the third quarter of 2022. Paul Stoffels3, CEO and Chairman of the Board of Directors of Galapagos, commented: “Today we ...
By Galapagos NV
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you